STOCK TITAN

G1 Therapeutics Inc - GTHX STOCK NEWS

Welcome to our dedicated news page for G1 Therapeutics (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.

Rhea-AI Summary
G1 Therapeutics grants inducement stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
G1 Therapeutics, Inc. reported total revenue of $42.4 million for Q2 2023, including $11.1 million in net COSELA revenue. They also reiterated the expectation for an interim overall survival analysis of their pivotal Phase 3 trial in metastatic triple negative breast cancer in Q1 2024. G1 presented new Phase 2 results confirming the benefit of Trilaciclib in reducing adverse events associated with an antibody-drug conjugate in TNBC. They also provided Phase 2 mechanism of action trial results clarifying Trilaciclib's role in enhancing immune surveillance and efficacy. G1 improved their financial strength by amending their debt facility and receiving payment from Simcere for relief of future royalties. They ended Q2 2023 with cash, cash equivalents, and marketable securities of $104.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
-
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) to participate in 2023 BTIG Virtual Biotechnology Conference on August 7, and 2023 Wedbush PacGrow Healthcare Conference on August 9. CEO Jack Bailey and team will engage in investor meetings. BTIG events are for prospective and existing clients only. Contact respective representatives for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Summary
G1 Therapeutics, Inc. will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on August 2, 2023, at 8:30 a.m. ET. Registration is required to access the call via telephone. A live and archived webcast will be available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Rhea-AI Summary
G1 Therapeutics presents Phase 2 trial results of trilaciclib in patients with triple-negative breast cancer. Trilaciclib enhances T cell function and generation of memory T cells, potentially improving long-term immune surveillance. The drug also increases the ratio of CD8+ T cells to regulatory T cells, which is associated with overall survival and pathologic complete response. Trilaciclib's mechanism of action protects the immune system from damage caused by cytotoxic therapy. The results suggest potential longer-term benefits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
none
-
Rhea-AI Summary
G1 Therapeutics appoints Monica Thomas as General Counsel and Chief Compliance Officer. The company also reports an inducement equity grant for Mrs. Thomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
none
G1 Therapeutics Inc

Nasdaq:GTHX

GTHX Rankings

GTHX Stock Data

237.51M
43.59M
11.68%
30.15%
5.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Research Triangle Park

About GTHX

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.